Opinion

Video

Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC

Gary D. Steinberg, MD, discusses the unmet needs and current standard of care for patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      1. What are some of the unmet needs in the treatment of non-muscle-invasive bladder cancer (NMIBC)?
      • Patients with intermediate and high risk NMIBC
      • Disease burden/effects on QoL

      2. What is the current standard of care for patients with intermediate-risk or high risk NMIBC?

      • Surgical resection
      • Discuss shortage of BCG
      Related Videos
      1 expert in this video
      Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
      2 experts are featured in this series.
      Treatment or Lack of Treatment of Small Renal Masses
      1 expert is featured in this series.
      The current treatment landscape of mHSPC
      2 experts are featured in this series.
      Strengths and Weaknesses of Imaging Modalities in ccRCC
      1 expert in this video
      BPH: Strategies for Guiding Patients From Medication to Intervention
      1 expert is featured in this series.
      Representation of Black men with mHSPC in clinical trials
      1 expert in this video
      Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
      4 experts in this video
      Non–Muscle Invasive-Bladder Cancer Overview
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      1 expert is featured in this series.
      BRCA Mutations in mHSPC: Impact on Therapy Selection
      Related Content
      FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
      May 21st 2025

      FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

      Hannah Clarke
      The committee voted 4-5 in opposition of a favorable benefit-risk profile.
      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
      May 17th 2025

      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

      Amy M. Pearlman, MD Alex Tatem, MD
      Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      May 9th 2025

      Durvalumab plus BCG significantly improves DFS in NMIBC

      Benjamin P. Saylor Hannah Clarke
      The data are to be presented at an upcoming medical conference.
      Physical function and frailty measures offer distinct insights in patients with bladder cancer
      May 7th 2025

      Physical function and frailty measures offer distinct insights in patients with bladder cancer

      Hannah Clarke
      Data showed that physical function and self-reported frailty assessments were poorly correlated.
      © 2025 MJH Life Sciences

      All rights reserved.